Yarrow Bioscience Inc (YARW)
Snapshot
- 1 week
- +0.1%+0.2% vs SPY
- 1 month
- -21.7%-20.9% vs SPY
- Market cap
- $17.2M
- P/E
- negindustry 15.0
- P/B
- 0.8
- EV/EBITDA
- -8.7
- FCF yield
- -9.1%
- Dividend yield
- 2.01%
- Days to cover
- 1.3
- Short change
- -30.4%
- Consensus
- Buy1 buy · 0 hold · 0 sell
- Price target
- $5.7571.3% downside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Yarrow Bioscience Inc (YARW). Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
- David T. DomzalskiChief Executive Officer, President & DirectorUSD 652K
- Iain A. StuartChief Scientific OfficerUSD 485K
- Mutya HarschGeneral Counsel, Chief Legal Officer & Company SecretaryUSD 473K
- Darrell S. RigelConsultantUSD 40K
- Tyler ZerondaChief Financial Officer & Treasurer
Snapshot
Price & returns1 month -21.7%
- 1 week
- +0.1%+0.2% vs SPY
- 1 month
- -21.7%-20.9% vs SPY
ValuationP/E neg vs industry 15.0 · market cap $17.2M
- Market cap
- $17.2M
- P/E
- negindustry 15.0
- P/B
- 0.8
- EV/EBITDA
- -8.7
- FCF yield
- -9.1%
IncomeYield 2.01%
- Dividend yield
- 2.01%
Short interest & optionsDays to cover 1.3 · Short change -30.4%
- Days to cover
- 1.3
- Short change
- -30.4%
Street & earningsTarget $5.75 (71.3% downside)1 buy · 0 hold · 0 sell
- Consensus
- Buy1 buy · 0 hold · 0 sell
- Price target
- $5.7571.3% downside
Signal evidence
Prediction markets
Kalshi · Polymarket · … linked
Company
Yarrow Bioscience Inc (YARW). Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
- David T. DomzalskiChief Executive Officer, President & DirectorUSD 652K
- Iain A. StuartChief Scientific OfficerUSD 485K
- Mutya HarschGeneral Counsel, Chief Legal Officer & Company SecretaryUSD 473K
- Darrell S. RigelConsultantUSD 40K
